Dose-rounding of adjuvant chemotherapy for breast cancer: An audit of toxicity

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 4, 2010, Pages 251-255

  Jenkins, Peter ^a   Wallis, Richard ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

breast cancer; chemotherapy; dose rounding

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; SEPSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY SURFACE AREA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG DOSAGE CALCULATIONS; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MEDICAL AUDIT; MIDDLE AGED; YOUNG ADULT;

EID: 78650458079     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209351304     Document Type: Article

References (10)

1. Plumridge R., Sewell G. Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy. Am J Health-Syst Pharm 2001 ; 58: 1760-1764.
2. Kaestner S., Sewell G. Chemotherapy Dosing Part II: Alternative approaches and future prospects. Clin Oncol 2007 ; 19: 99-107.
3. Dooley M., Singh S., Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Suppot Care Cancer 2004 ; 12: 653-656.
4. Baker J., Jones S. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Practice 1998 ; 4: 10-14.
5. Jenkins P., Elyan S., Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 2007 ; 43: 544-548.
6. Mouridsen H., Andersen J., Andersson M., Dombernowsky P., Ejlertsen B., Rose C. et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proceedings of Am Soc Clin Oncol 1999 ; 19: 68a (abstr 254 ).
7. DuBois D., DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916 ; 17: 863-871.
8. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996 ; 14: 2590-611.
9. Group FAS. Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001 ; 19: 599-601.
10. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995 ; 332: 901-6.